Virginia Department of Health
State Board of Health
Prescription Drug Price Transparency Regulation
[12 VAC 5 ‑ 219]
On this Action:
CLOSED Opened on 1/17/2022 and Ended on 2/16/2022
View all comments
4 comments
| Comment Title | Commenter | |
|---|---|---|
| Recommend explicitly excl CMOs [and similar org] who manufacture but do not market or set prices | Catalent Pharma Solutions, Inc. | 2/14/22 6:21 pm |
| Suggestion to exempt Contract Manufacturing Organizations from requirement | Gil Roth, Pharma & Biophama Outsourcing Association (PBOA) | 2/15/22 5:04 pm |
| Request Clarification of Manufacturer and Reporting Entity. | Pharma Solutions USA, Inc., Sumeet Singh CEO & Deneen Fumich, Director | 2/16/22 11:08 am |
| PhRMA Comments re Chapter 219 Prescription Drug Price Transparency Regulation | PhRMA | 2/16/22 5:15 pm |
Trouble posting comments? These pages have been tested with multiple versions of all the major browsers.
If you have trouble: (1) try another computer if you have access to one, (2) try another browser if your computer has one installed (3) contact
Town Hall support staff for assistance.